Search

Your search keyword '"van Wijk, F"' showing total 346 results
Start Over Author "van Wijk, F"
346 results on '"van Wijk, F"'

1. POS0156 CD4+HLADR+ T CELLS WITH AUTOIMMUNE REACTIVITY THAT RESIST REGULATORY CONTROL AND PERPETUATE DISEASE INFLAMMATION IN JUVENILE IDIOPATHIC ARTHRITIS

Author

Leong, J. Y., primary, Kumar, P., additional, Tay, S. H., additional, Mijnheer, G., additional, Yeo, J. G., additional, Hazirah, S., additional, Lim, A. J. M., additional, Chua, C., additional, Chen, P., additional, Consolaro, A., additional, Gattorno, M., additional, Arkachaisri, T., additional, Van Wijk, F., additional, Martini, A., additional, and Albani, S., additional

Published
2024
Full Text
View/download PDF

3. Improving the Adhesion Robustness of 2K Michael Addition Coating Systems

Author

Noordover, B., Looij, N., Kalis, J., Koeken, R., Van Wijk, F., De Wolf, E., Gessner, M., McCracken, E., DeGooyer, B., Brinkhuis, R., Zhang, Y., Buser, T., and Lunzerallnex, F.

Subjects
Carbonates -- Research, Epoxy resins -- Usage, Coatings industry -- Technology application, Robustness (Statistics) -- Usage, Hydroxides, Technology application, Business, Chemicals, plastics and rubber industries
Abstract

Recently, two-component (2K) Michael Addition-based coating systems providing fast drying at room temperature in combination with tunable open time and very long pot life have entered the market. Adhesion robustness over a variety of substrates is an important point of attention for such fast drying and inherently rather apolar coating systems. Here, we present a study that resulted in new malonated polyester resins facilitating a significantly improved adhesion performance of the Michael Addition-based coatings, especially over epoxy-amine and polyurethane primer substrates. Notably, the introduction of hydroxyl groups is an effective way to improve properties such as wet adhesion., INTRODUCTION In 2015, a breakthrough high solids two-component (2K) coatings system was introduced, based on Real (or Carbon) Michael Addition (RMA) chemistry. (1) In this base-catalyzed system, malonated polyester donor [...]

Published
2019

9. Unraveling heterogeneity in pediatric atopic dermatitis:: identification of serum biomarker based patient clusters

Author

MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CDL Patiëntenzorg MI, CTI Research, Cancer, CTI Bont, CTI UDAIR, CTI Van Wijk, Child Health, CTI Computational Immunology Core, Bakker, D., de Graaf, M., Nierkens, S., Delemarre, E., Knol, E., van Wijk, F., de Bruin-Weller, M., Drylewicz, J., Thijs, J., MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CDL Patiëntenzorg MI, CTI Research, Cancer, CTI Bont, CTI UDAIR, CTI Van Wijk, Child Health, CTI Computational Immunology Core, Bakker, D., de Graaf, M., Nierkens, S., Delemarre, E., Knol, E., van Wijk, F., de Bruin-Weller, M., Drylewicz, J., and Thijs, J.

Published
2022

13. Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + RORγt + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies.

Author

Pouw, J. N. Juliëtte, Nordkamp, M. A. M. Michel Olde, van Kempen, T. Tessa, Concepcion, A. N. Arno, van Laar, J. M. Jacob, van Wijk, F. Femke, Spierings, J. Julia, Leijten, E. F. A. Emmerik, and Boes, M. Marianne

Subjects
REGULATORY T cells, MONONUCLEAR leukocytes, PSORIATIC arthritis, SYNOVIAL fluid, JOINT pain, T cells
Abstract

In psoriatic arthritis (PsA), predisposing class I HLA alleles, the presence of synovial clonally proliferated CD8 + T cells and autoantibodies all point towards the loss of immune tolerance. However, the key mechanisms that lead to immune dysregulation are not fully understood. In other types of inflammatory arthritis, T regulatory cell (Treg) dysfunction and plasticity at sites of inflammation were suggested to negatively affect peripheral tolerance. We here addressed if Treg variances associate with psoriatic disease. We collected clinical data, sera and peripheral blood mononuclear cells from 13 healthy controls, 21 psoriasis and 21 PsA patients. In addition, we obtained synovial fluid mononuclear cells from 6 PsA patients. We studied characteristics of CD4 + CD25 + CD127loFoxp3 + Tregs by flow cytometry and used ELISA to quantify antibodies against ADAMTSL5, a recently discovered autoantigen in psoriatic disease. In comparison with their circulating counterparts, Tregs from inflamed joints express increased levels of ICOS, CTLA-4 and TIGIT. Furthermore, synovial fluid-derived Tregs have a distinct phenotype, characterized by IL-17A production and upregulation of CD161 and RORγt. We identified a subset of Tregs with intermediate Foxp3 expression as the major cytokine producer. Furthermore, ICOS + Tregs associate with PsA disease activity as measured by PASDAS. Lastly, we observed that presence of the Foxp3int Tregs associates with an increased abundance of anti-ADAMTSL5 autoantibodies. Tregs derived from the inflammatory environment of inflamed PsA joints exhibit a distinct phenotype, which associates with loss of peripheral immune tolerance in psoriatic disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. COMPARTMENTALIZATION, PERSISTENCE AND CONSERVED SHARED MOTIFS OF DOMINANT (REGULATORY) T CELL CLONES IN AUTOIMMUNE INFLAMMATION

Author

Infection & Immunity, CTI Pandit, CTI Van Wijk, CDL Patiëntenzorg MI, Cancer, CTI Van Loosdregt, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Lab Reumatologie/Klinische Immunologie, Mijnheer, G., Servaas, N., Lutter, L., Leong, J. Y., Spierings, E., Chen, P., Petrelli, A., Vastert, S., de Boer, R., Albani, S., van Loosdregt, J., Pandit, A., van Wijk, F., Infection & Immunity, CTI Pandit, CTI Van Wijk, CDL Patiëntenzorg MI, Cancer, CTI Van Loosdregt, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Lab Reumatologie/Klinische Immunologie, Mijnheer, G., Servaas, N., Lutter, L., Leong, J. Y., Spierings, E., Chen, P., Petrelli, A., Vastert, S., de Boer, R., Albani, S., van Loosdregt, J., Pandit, A., and van Wijk, F.

Published
2021

15. Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4+ and CD8+ T-cell clusters in systemic sclerosis

Author

CTI Pandit, DBG Metabole en Endocriene Ziekten, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, Other research (not in main researchprogram), Translationele immunologie, CTI Meyaard, CTI Van Wijk, Child Health, CTI Radstake, Servaas, N H, Zaaraoui-Boutahar, F, Wichers, C G K, Ottria, A, Chouri, E, Affandi, A J, Silva-Cardoso, S, van der Kroef, M, Carvalheiro, T, van Wijk, F, Radstake, T R D J, Andeweg, A C, Pandit, A, CTI Pandit, DBG Metabole en Endocriene Ziekten, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, Other research (not in main researchprogram), Translationele immunologie, CTI Meyaard, CTI Van Wijk, Child Health, CTI Radstake, Servaas, N H, Zaaraoui-Boutahar, F, Wichers, C G K, Ottria, A, Chouri, E, Affandi, A J, Silva-Cardoso, S, van der Kroef, M, Carvalheiro, T, van Wijk, F, Radstake, T R D J, Andeweg, A C, and Pandit, A

Published
2021

21. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool For Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis

Author

Wienke, J, Pachman, LM, Morgan, GA, Yeo, JG, Amoruso, MC, Hans, V, Kamphuis, Sylvia, Hoppenreijs, E, Armbrust, W, Berg, JM, Muller, P, Gelderman, KA, Arkachaisri, T, van Wijk, F, van Royen-kerkhof, A, Wienke, J, Pachman, LM, Morgan, GA, Yeo, JG, Amoruso, MC, Hans, V, Kamphuis, Sylvia, Hoppenreijs, E, Armbrust, W, Berg, JM, Muller, P, Gelderman, KA, Arkachaisri, T, van Wijk, F, and van Royen-kerkhof, A

Published
2020

22. Colonic mucosal kinase activity, cytokine and chemokine profiles in inflammatory bowel disease

Author

MS MDL 1, Translationele immunologie, CTI Van Wijk, Child Health, Infection & Immunity, Brand, E., Roosenboom, B., Fernandez, B. Malvar, Lutter, L., van Koolwijk, E., van Lochem, E. G., Horje, C. S. Horjus Talabur, Reedquist, K. A., van Wijk, F., Oldenburg, B., MS MDL 1, Translationele immunologie, CTI Van Wijk, Child Health, Infection & Immunity, Brand, E., Roosenboom, B., Fernandez, B. Malvar, Lutter, L., van Koolwijk, E., van Lochem, E. G., Horje, C. S. Horjus Talabur, Reedquist, K. A., van Wijk, F., and Oldenburg, B.

Published
2020

25. Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4+ and CD8+ T-cell clusters in systemic sclerosis

Author

Servaas, N.H., primary, Zaaraoui-Boutahar, F., additional, Wichers, C.G.K., additional, Ottria, A., additional, Chouri, E., additional, Affandi, A.J., additional, Silva-Cardoso, S., additional, van der Kroef, M., additional, Carvalheiro, T., additional, van Wijk, F., additional, Radstake, T.R.D.J., additional, Andeweg, A.C., additional, and Pandit, A., additional

Published
2021
Full Text
View/download PDF

28. Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4+ and CD8+ T-cell clusters in Systemic Sclerosis

Author

Servaas, N.H., primary, Zaaraoui-Boutahar, F., additional, Wichers, C.G.K., additional, Ottria, A., additional, Chouri, E., additional, Affandi, A.J., additional, Silva-Cardoso, S., additional, van der Kroef, M., additional, Carvalheiro, T., additional, van Wijk, F., additional, Radstake, T.R.D.J., additional, Andeweg, A.C., additional, and Pandit, A., additional

Published
2020
Full Text
View/download PDF

29. THU0047 THE SYNOVIUM REWIRES AN IMMUNOLOGICAL RHEOSTAT THAT DEFINES TWO FUNCTIONALLY DISPARATE PATHOGENIC CD4+HLA-DR+ SUBSETS IN HUMAN ARTHRITIS

Author

Leong, J. Y., primary, Kumar, P., additional, Mijnheer, G., additional, Chen, P., additional, Yeo, J. G., additional, Tay, S. H., additional, Chua, C., additional, Hazirah, S. N., additional, Lai, L., additional, Consolaro, A., additional, Gattorno, M., additional, Arkachaisri, T., additional, Martini, A., additional, Van Wijk, F., additional, and Albani, S., additional

Published
2020
Full Text
View/download PDF

34. Dupilumab : Eerste resultaten vanuit het BioDay-register

Author

Ariëns, Lieneke F.M., van der Schaft, J., Bakker, D. S., Balak, D. M.W., Giovannone, B., Romeijn, M., Kouwenhoven, T., Kamsteeg, M., Drylewicz, J., van Wijk, F., Nierkens, Stefan, Thijs, J. L., Schuttelaar, M. L., and de Bruin-Weller, M. S.

Subjects
Infectious Diseases, Biologic, Dupilumab, Daily practice, Critical Care and Intensive Care Medicine, Atopic dermatitis
Abstract

The effectiveness and safety of dupilumab for the treatment of moderate to severe atopic dermatitis (AD) has been demonstrated in phase III clinical trials. At this moment, daily practice data on dupilumab treatment with respect to clinical effectiveness and safety are scarce. The objective of this study was to study the clinical effectiveness of 16 weeks treatment with dupilumab in adult patients with moderate to severe AD in daily practice. Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen-weeks clinical effectiveness of dupilumab was expressed as number of patients achieving EASI-50, EASI-75 as well as patient reported outcome measures (POEM, DLQI, NRS-pruritus). A clinically relevant response was defined based on thresholds in one or more outcomes of the 3 major AD domains (EASI, NRS-pruritus, DLQI). In total, 138 patients treated with dupilumab in daily practice were included. This cohort included patients with very difficult- to-treat AD with 84 patients (61%) who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI-50 and EASI-75 was achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. Also patient-reported outcomes including sleep, itch and quality of life significantly improved during dupilumab treatment. A clinically relevant response was achieved by 89% of the patients after 16 weeks of treatment. The most reported side effects were conjunctivitis in 47 (34%) and eosinophilia in 78 (57%) patients. In conclusion, treatment with dupilumab significantly improved signs and symptoms of AD in patients with very difficult-to-treat AD in a daily practice setting with the majority of patients achieving a clinically relevant response after 16 weeks of treatment.

Published
2019

41. The identification of CCL18 as biomarker of disease activity in localized scleroderma

Author

Mertens, J. S., de Jong, E. M.G.J., van den Hoogen, L. L., Wienke, J., Thurlings, R. M., Seyger, M. M.B., Hoppenreijs, E. P.A.H., Wijngaarde, C. A., van Vlijmen-Willems, I. M.J.J., van den Bogaard, E., Giovannone, B., van Wijk, F., van Royen-Kerkhof, A., Marut, W., Radstake, T. R.D., Mertens, J. S., de Jong, E. M.G.J., van den Hoogen, L. L., Wienke, J., Thurlings, R. M., Seyger, M. M.B., Hoppenreijs, E. P.A.H., Wijngaarde, C. A., van Vlijmen-Willems, I. M.J.J., van den Bogaard, E., Giovannone, B., van Wijk, F., van Royen-Kerkhof, A., Marut, W., and Radstake, T. R.D.

Published
2019

42. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation

Author

Wienke, J., Enders, F.B., Lim, J, Mertens, J.S., van den Hoogen, L. L., Wijngaarde, C.A., Yeo, J.G., Meyer, A. (Andreas), Otten, H.G. (Henderikus), Fritsch-Stork, R. D. E., Kamphuis, S.S.M. (Sylvia), Hoppenreijs, E., Armbrust, W. (Wineke), van den Berg, J.M., Muller, P., Tekstra, J., Hoogendijk, J.E., Deakin, C.T., Jager, W. (Wilco) de, Roon, J.A.G. (J. A G) van, Pol, W.-L. (W-Ludo) van der, Nistala, K., Pilkington, C., Visser, M. (Mirjam), Arkachaisri, T., Radstake, T, Kooj, A.J. (Anneke), Nierkens, S., Wedderburn, L.R. (Lucy), van Royen-kerkhof, A., van Wijk, F., Wienke, J., Enders, F.B., Lim, J, Mertens, J.S., van den Hoogen, L. L., Wijngaarde, C.A., Yeo, J.G., Meyer, A. (Andreas), Otten, H.G. (Henderikus), Fritsch-Stork, R. D. E., Kamphuis, S.S.M. (Sylvia), Hoppenreijs, E., Armbrust, W. (Wineke), van den Berg, J.M., Muller, P., Tekstra, J., Hoogendijk, J.E., Deakin, C.T., Jager, W. (Wilco) de, Roon, J.A.G. (J. A G) van, Pol, W.-L. (W-Ludo) van der, Nistala, K., Pilkington, C., Visser, M. (Mirjam), Arkachaisri, T., Radstake, T, Kooj, A.J. (Anneke), Nierkens, S., Wedderburn, L.R. (Lucy), van Royen-kerkhof, A., and van Wijk, F.

Abstract

Objective. Objective evaluation of disease activity is challenging in patients with juvenile dermatomyositis (DM) due to a lack of reliable biomarkers, but it is crucial to avoid both under- and overtreatment of patients. Recently, we identified 2 proteins, galectin-9 and CXCL10, whose levels are highly correlated with the extent of juvenile DM disease activity. This study was undertaken to validate galectin-9 and CXCL10 as biomarkers for disease activity in juvenile DM, and to assess their disease specificity and potency in predicting the occurrence of flares. Methods. Levels of galectin-9 and CXCL10 were measured by multiplex immunoassay in serum samples from 125 unique patients with juvenile DM in 3 international cross-sectional cohorts and a local longitudinal cohort. The disease specificity of both proteins was examined in 50 adult patients with DM or nonspecific myositis (NSM) and 61 patients with other systemic autoimmune diseases. Results. Both cross-sectionally and longitudinally, galectin-9 and CXCL10 outperformed the currently used laboratory marker, creatine kinase (CK), in distinguishing between juvenile DM patients with active disease and those in remission (area under the receiver operating characteristic curve [AUC] 0.86–0.90 for galectin-9 and CXCL10; AUC 0.66–0.68 for CK). The sensitivity and specificity for active disease in juvenile DM was 0.84 and 0.92, respectively, for galectin-9 and 0.87 and 1.00, respectively, for CXCL10. In 10 patients with juvenile DM who experienced a flare and were prospectively followed up, continuously elevated or rising biomarker levels suggested an imminent flare up to several months before the onset of symptoms, even in the absence of elevated CK levels. Galectin-9 and CXCL10 distinguished between active disease and remission in adult patients with DM or NSM (P = 0.0126 for galectin-9 and P < 0.0001 for CXCL10) and were suited for measurement in minimally invasive dried blood spots (healthy controls versus juvenile

Published
2019
Full Text
View/download PDF

44. Dupilumab: Eerste resultaten vanuit het BioDay-register

Author

MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI Borghans, CTI Van Wijk, Child Health, CTI Research, CDL Patiëntenzorg MI, CTI Nierkens, CTI UDAIR, Ariëns, Lieneke F.M., van der Schaft, J., Bakker, D. S., Balak, D. M.W., Giovannone, B., Romeijn, M., Kouwenhoven, T., Kamsteeg, M., Drylewicz, J., van Wijk, F., Nierkens, Stefan, Thijs, J. L., Schuttelaar, M. L., de Bruin-Weller, M. S., MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI Borghans, CTI Van Wijk, Child Health, CTI Research, CDL Patiëntenzorg MI, CTI Nierkens, CTI UDAIR, Ariëns, Lieneke F.M., van der Schaft, J., Bakker, D. S., Balak, D. M.W., Giovannone, B., Romeijn, M., Kouwenhoven, T., Kamsteeg, M., Drylewicz, J., van Wijk, F., Nierkens, Stefan, Thijs, J. L., Schuttelaar, M. L., and de Bruin-Weller, M. S.

Published
2019

45. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

Author

MS Dermatologie/Allergologie, MS Oogheelkunde, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Immuno/reuma onderzoek 4, Onderzoek, Child Health, Infection & Immunity, CTI, Pathologie Pathologen staf, Cancer, Bakker, D S, Ariens, L F M, van Luijk, C, van der Schaft, J, Thijs, J L, Schuttelaar, M L A, van Wijk, F, Knol, E F, Balak, D M W, van Dijk, M R, de Bruin-Weller, M S, MS Dermatologie/Allergologie, MS Oogheelkunde, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Immuno/reuma onderzoek 4, Onderzoek, Child Health, Infection & Immunity, CTI, Pathologie Pathologen staf, Cancer, Bakker, D S, Ariens, L F M, van Luijk, C, van der Schaft, J, Thijs, J L, Schuttelaar, M L A, van Wijk, F, Knol, E F, Balak, D M W, van Dijk, M R, and de Bruin-Weller, M S

Published
2019

46. The identification of CCL18 as biomarker of disease activity in localized scleroderma

Author

UMC Utrecht, Translationele immunologie, Infection & Immunity, CTI Van Wijk, Opleiding Neurologie, Brain, Immuno/reuma onderzoek 4, Child Health, Immuno/reuma patientenzorg, CTI Radstake, Mertens, J. S., de Jong, E. M.G.J., van den Hoogen, L. L., Wienke, J., Thurlings, R. M., Seyger, M. M.B., Hoppenreijs, E. P.A.H., Wijngaarde, C. A., van Vlijmen-Willems, I. M.J.J., van den Bogaard, E., Giovannone, B., van Wijk, F., van Royen-Kerkhof, A., Marut, W., Radstake, T. R.D., UMC Utrecht, Translationele immunologie, Infection & Immunity, CTI Van Wijk, Opleiding Neurologie, Brain, Immuno/reuma onderzoek 4, Child Health, Immuno/reuma patientenzorg, CTI Radstake, Mertens, J. S., de Jong, E. M.G.J., van den Hoogen, L. L., Wienke, J., Thurlings, R. M., Seyger, M. M.B., Hoppenreijs, E. P.A.H., Wijngaarde, C. A., van Vlijmen-Willems, I. M.J.J., van den Bogaard, E., Giovannone, B., van Wijk, F., van Royen-Kerkhof, A., Marut, W., and Radstake, T. R.D.

Published
2019

47. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation

Author

Wienke, J, Enders, FB, Lim, J, Mertens, JS, van den Hoogen, L L, Wijngaarde, CA, Yeo, JG, Meyer, A, Otten, HG, Fritsch-Stork, R D E, Kamphuis, Sylvia, Hoppenreijs, E, Armbrust, W, Berg, JM, Muller, P, Tekstra, J, Hoogendijk, JE, Deakin, CT, de Jager, W, van Roon, JAG, van der Pol, WL, Nistala, K, Pilkington, C, Visser, M, Arkachaisri, T, Radstake, T, van der Kooi, AJ, Nierkens, S, Wedderburn, LR, van Royen-kerkhof, A, van Wijk, F, Wienke, J, Enders, FB, Lim, J, Mertens, JS, van den Hoogen, L L, Wijngaarde, CA, Yeo, JG, Meyer, A, Otten, HG, Fritsch-Stork, R D E, Kamphuis, Sylvia, Hoppenreijs, E, Armbrust, W, Berg, JM, Muller, P, Tekstra, J, Hoogendijk, JE, Deakin, CT, de Jager, W, van Roon, JAG, van der Pol, WL, Nistala, K, Pilkington, C, Visser, M, Arkachaisri, T, Radstake, T, van der Kooi, AJ, Nierkens, S, Wedderburn, LR, van Royen-kerkhof, A, and van Wijk, F

Published
2019

50. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Author

Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., and Vermorken, J. B.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results